Compare Stocks: IBRX, RVMD, BIIB, and ALNY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$224.47 +0.3%	$238.83	$197.81 ▼ $495.55	$30.04B	0.28	1.44 million shs	1.11 million shs
BIIB Biogen	$232.83 +1.7%	$218.89	$138.00 ▼ $238.24	$34.40B	0.09	1.20 million shs	1.95 million shs
IBRX ImmunityBio	$9.91 +1.1%	$8.43	$1.95 ▼ $12.43	$10.50B	0.02	20.62 million shs	29.89 million shs
RVMD Revolution Medicines	$193.52 +2.7%	$203.93	$47.45 ▼ $224.31	$41.48B	1.4	2.86 million shs	2.46 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-1.41%	-0.05%	-10.00%	-19.82%	-51.86%
BIIB Biogen	-0.22%	+2.70%	+5.41%	+16.05%	+58.20%
IBRX ImmunityBio	-3.16%	+1.14%	+23.89%	+26.78%	+295.16%
RVMD Revolution Medicines	-2.84%	-5.72%	-7.52%	+2.17%	+286.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$224.47 +0.3%	$238.83	$197.81 ▼ $495.55	$30.04B	0.28	1.44 million shs	1.11 million shs
BIIB Biogen	$232.83 +1.7%	$218.89	$138.00 ▼ $238.24	$34.40B	0.09	1.20 million shs	1.95 million shs
IBRX ImmunityBio	$9.91 +1.1%	$8.43	$1.95 ▼ $12.43	$10.50B	0.02	20.62 million shs	29.89 million shs
RVMD Revolution Medicines	$193.52 +2.7%	$203.93	$47.45 ▼ $224.31	$41.48B	1.4	2.86 million shs	2.46 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-1.41%	-0.05%	-10.00%	-19.82%	-51.86%
BIIB Biogen	-0.22%	+2.70%	+5.41%	+16.05%	+58.20%
IBRX ImmunityBio	-3.16%	+1.14%	+23.89%	+26.78%	+295.16%
RVMD Revolution Medicines	-2.84%	-5.72%	-7.52%	+2.17%	+286.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.88	Moderate Buy	$365.50	62.24% Upside
BIIB Biogen	2.59	Moderate Buy	$236.04	1.72% Upside
IBRX ImmunityBio	2.86	Moderate Buy	$14.20	43.23% Upside
RVMD Revolution Medicines	2.92	Moderate Buy	$234.81	21.54% Upside

Current Analyst Ratings Breakdown

Latest IBRX, RVMD, BIIB, and ALNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/14/2026	ALNY Alnylam Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$340.00 ➝ $320.00
10/14/2026	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Equal Weight	$256.00 ➝ $253.00
10/14/2026	RVMD Revolution Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$259.00 ➝ $260.00
10/12/2026	BIIB Biogen	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Perform	$220.00
10/12/2026	BIIB Biogen	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Overweight	$210.00 ➝ $300.00
10/9/2026	BIIB Biogen	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$240.00 ➝ $270.00
10/8/2026	RVMD Revolution Medicines	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/8/2026	ALNY Alnylam Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$350.00 ➝ $345.00
10/8/2026	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$260.00 ➝ $256.00
10/8/2026	RVMD Revolution Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$251.00 ➝ $259.00
10/7/2026	RVMD Revolution Medicines	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$239.00 ➝ $240.00

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	8.12	$2.77 per share	81.19	$5.97 per share	37.74
BIIB Biogen	$9.89B	3.47	$22.88 per share	10.14	$124.45 per share	1.86
IBRX ImmunityBio	$113.29M	92.75	N/A	N/A	($0.51) per share	-19.44
RVMD Revolution Medicines	$11.58M	3,575.96	N/A	N/A	$8.44 per share	22.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	41.78	23.22	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	41.13	14.37	2.53	8.32%	11.18%	6.88%	10/28/2026 (Estimated)
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	11/3/2026 (Estimated)
RVMD Revolution Medicines	-$1.13B	-$8.82	N/A	N/A	N/A	N/A	-88.20%	-57.85%	11/4/2026 (Estimated)

Latest IBRX, RVMD, BIIB, and ALNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	RVMD Revolution Medicines	-$2.35	N/A	N/A	N/A	$23.74 million	N/A
11/3/2026	Q3 2026	IBRX ImmunityBio	-$0.07	N/A	N/A	N/A	$59.23 million	N/A
10/29/2026	Q3 2026	ALNY Alnylam Pharmaceuticals	$1.75	N/A	N/A	N/A	$1.43 billion	N/A
10/28/2026	Q3 2026	BIIB Biogen	$2.02	N/A	N/A	N/A	$2.64 billion	N/A
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	-$3.06	-$1.02	-$3.06	$1.77 million	N/A
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
BIIB Biogen	0.39	1.87	1.26
IBRX ImmunityBio	N/A	5.72	5.70
RVMD Revolution Medicines	0.40	11.38	11.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
IBRX ImmunityBio	8.58%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
IBRX ImmunityBio	66.10%
RVMD Revolution Medicines	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
IBRX ImmunityBio	691	1.06 billion	359.28 million	Optionable
RVMD Revolution Medicines	883	214.34 million	198.05 million	Optionable

IBRX, RVMD, BIIB, and ALNY Headlines

Recent News About These Companies

Revolution Medicines (NASDAQ:RVMD) Shares Climb 3.4% Following Analyst Upgrade

October 14 at 11:39 AM | marketbeat.com

Royal Bank Of Canada Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock

October 14 at 10:00 AM | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Stock Has Average Target Price of $234.76 According to Brokerages

October 14 at 2:15 AM | americanbankingnews.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Stock Has Average Target Price of $234.76 According to Analysts

October 14 at 2:13 AM | marketbeat.com

Rasonque subgroup data put KRAS response differences in focus

October 12 at 9:05 AM | thepharmaletter.comT

Financial Analysis: Evogene (NASDAQ:EVGN) versus Revolution Medicines (NASDAQ:RVMD)

October 12 at 4:45 AM | americanbankingnews.com

Guggenheim Sticks to Its Buy Rating for Revolution Medicines (RVMD)

October 11 at 7:13 AM | theglobeandmail.com

Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

October 10, 2026 | americanbankingnews.com

RBC Raises Price Target on Revolution Medicines to $259 From $251, Keeps Outperform Rating

October 8, 2026 | finance.yahoo.com

Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $259.00

October 8, 2026 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Stock Falls 4.3% - Here's What Happened

October 6, 2026 | marketbeat.com

Revolution Medicines Begins Phase 3 Trial of Rasonque Combination in Pancreatic Cancer

October 5, 2026 | finance.yahoo.com

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

October 5, 2026 | globenewswire.com

Revolution Medicines (NASDAQ: RVMD) CDO sells 6,309 shares under preset plan

October 5, 2026 | americanbankingnews.com

Revolution Medicines: Priced For A Label The Trial Didn't Test; Hold

October 3, 2026 | seekingalpha.com

Revolution Medicines (NASDAQ:RVMD) Stock: Insider Alan Sandler Sells 6,309 Shares

October 3, 2026 | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Insider Alan Sandler Sells 6,309 Shares of Stock

October 1, 2026 | marketbeat.com

Analysts Issue Forecasts for RVMD FY2027 Earnings

September 30, 2026 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Stock Picked Up by Analysts at Brookline Capital Markets

September 28, 2026 | marketbeat.com

Bernstein Sticks to Their Hold Rating for Revolution Medicines (RVMD)

September 27, 2026 | theglobeandmail.com

Revolution Medicines (RVMD) Gets a Buy from Goldman Sachs

September 25, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IBRX, RVMD, BIIB, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$224.47 +0.65 (+0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$225.23 +0.76 (+0.34%)

As of 07:21 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$232.83 +3.93 (+1.72%)

Closing price 04:00 PM Eastern

Extended Trading

$235.00 +2.17 (+0.93%)

As of 07:18 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

ImmunityBio NASDAQ:IBRX

$9.91 +0.11 (+1.12%)

Closing price 04:00 PM Eastern

Extended Trading

$9.98 +0.06 (+0.66%)

As of 07:23 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Revolution Medicines NASDAQ:RVMD

$193.52 +5.08 (+2.70%)

Closing price 04:00 PM Eastern

Extended Trading

$189.38 -4.14 (-2.14%)

As of 07:17 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBRX, RVMD, BIIB, and ALNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBRX, RVMD, BIIB, and ALNY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBRX, RVMD, BIIB, and ALNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IBRX, RVMD, BIIB, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

ImmunityBio NASDAQ:IBRX

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBRX, RVMD, BIIB, and ALNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBRX, RVMD, BIIB, and ALNY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBRX, RVMD, BIIB, and ALNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IBRX, RVMD, BIIB, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

ImmunityBio NASDAQ:IBRX

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools